A.R.T. Advisors’s Cogent Biosciences COGT Stock Holding History

A.R.T. Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,588	Closed	-$15K	–	1392
2019 Q3	$15K	Buy	+2,588	New	+$21K	﹤0.01%	1379

Other funds holding COGT

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

A.R.T. Advisors's COGT Position: Q4 2019 in Review

A.R.T. Advisors sold out of Cogent Biosciences (COGT) in Q4 2019, closing a stake of 2,588 shares — an estimated $15K sold.

A.R.T. Advisors first reported a position in COGT in Q3 2019 and held it in 1 quarter. The position peaked at $15K in Q3 2019. 27 funds tracked by Wall St. Rank hold COGT as of Q4 2019.

A.R.T. Advisors reported no remaining Cogent Biosciences position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 2,588 Cogent Biosciences shares in Q4 2019, an estimated $15K.
A.R.T. Advisors first reported a position in Cogent Biosciences in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Cogent Biosciences position peaked at $15K in Q3 2019.
27 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.